Manoj Kumar Patta¹, Soundappan Somasundaram¹*, Vijai Anand¹, Nalankilli VP¹, Srinivasan Muthukrishnan¹ and Srikanth B²

¹GEM Hospital and Research Center, Surgical Gastroenterology, India
²GEM Hospital and Research Center, Radiology, India

*Corresponding Author: Soundappan Somasundaram, GEM Hospital and Research Center, Surgical Gastroenterology, India.

Received: November 06, 2021; Published: December 30, 2021

Abstract

Hepatocellular carcinoma is the sixth most common cancer in the world, which accounts for approximately 6% of all cancer incidences [1]. Compared to other neoplasms, HCC patients are more susceptible to the effects of the COVID-19 pandemic as the hepatic injury caused by SARS-CoV-2 could complicate the pre-existing hepatitis virus infection and cirrhosis in most HCC patients [2]. COVID-19 also causes organ dysfunction, complicating cancer treatment. With the outbreak of COVID-19, modifications of cancer management have been adopted to accommodate the crisis and minimize the exposure of cancer patients to the infection. COVID 19 pandemic has led to treatment delays and also change in management protocols. Here we present a case of HCC patient affected by COVID and post COVID treatment complications and it’s sequelae, managed effectively with multidisciplinary approach.

Keywords: COVID-19; SARS-CoV-2; Hepatocellular Carcinoma

References

1. Siegel RL., et al. Cancer statistics. CA Cancer J Clin1(2020): 7-30.
2. Chan SL and Kudo M. “Impacts of COVID-19 on Liver Cancers: During and after the Pandemic”. Liver Cancer 9 (2020): 491-502.
3. Guan WJ., et al. “China Medical Treatment Expert Group for Covid-19. Clinical characteristics of coronavirus disease 2019 in China”. The New England Journal of Medicine18 (2020): 1708-1720.
4. Yang X., et al. “Clinical course and outcomes of critically ill patients with SARSCoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study”. The Lancet Respiratory Medicine5 (2020): 475-481.
5. Chen N., et al. “Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study”. Lancet10223 (2020): 507-513.
6. Huang C., et al. “Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China”. Lancet10223 (2020): 497-506.
7. Shi H., et al. “Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study”. The Lancet Infectious Diseases4 (2020): 425-34.
8. Wang D., et al. “Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China”. JAMA11 (2020): 1061-1069.
9. Xu XW., et al. “Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan, China: retrospective case series”. BMJ 368 (2020): m606.
10. Zhao D., et al. “A comparative study on the clinical features of COVID-19 pneumonia to other pneumonias”. Clinical Infectious Diseases15 (2020): 756-761.
11. Zhang C., et al. “Liver injury in COVID-19: management and challenges”. Lancet Gastroenterol Hepatol5 (2020): 428-430.
12. Wong SH., et al. “Covid-19 and the digestive system”. Journal of Gastroenterology and Hepatology5 (2020): 744-748.
13. Xu L., et al. “Liver injury during highly pathogenic human coronavirus infections”. Liver International5 (2020): 998-1004.
14. Genovese MC., et al. “Transaminase Levels and Hepatic Events During Tocilizumab Treatment: Pooled Analysis of Long-Term Clinical Trial Safety Data in Rheumatoid Arthritis”. Arthritis & Rheumatology9 (2017): 1751-1761.
15. Liang W., et al. “Cancer patients in SARS-CoV-2 infection: a nation wide analysis in China”. The Lancet Oncology3 (2020): 335-337.
16. Xia Y., et al. “Risk of COVID-19 for patients with cancer”. The Lancet Oncology4 (2020): e180.
17. Amaddeo G., et al. “Impact of COVID-19 on the management of hepatocellular carcinoma in a high-prevalence area”. Journal of High Energy Physics1.
18. M G., et al. “Impact of COVID-19 on Hepatocellular Carcinoma Management: A Multicountry and Region Study”. Journal of hepatocellular carcinoma (2021).
19. Fix OK., et al. “Clinical Best Practice Advice for Hepatology and Liver Transplant Providers During the COVID-19 Pandemic: AASLD Expert Panel Consensus Statement”. Hepatology 72 (2020): 287-304.
20. Boettler T., et al. “Care of patients with liver disease during the COVID-19 pandemic: EASL-ESCMID position paper”. Journal of Hepatology 2 (2020): 100113.
21. Meyer T., et al. Management of HCC during COVID-19: ILCA guidance. ILCA (2020).
22. Shiina S., et al. “APASL practical recommendations for the management of hepatocellular carcinoma in the era of COVID-19”. Hepatology International 14 (2020): 920-929.
23. Chagas AL., et al. “Management of Hepatocellular Carcinoma during the COVID-19 Pandemic - São Paulo Clínicas Liver Cancer Group Multidisciplinary Consensus Statement”. Clinics (Sao Paulo) 75 (2020): e2192.

Citation

Citation: Soundappan Somasundaram., et al. “Multidisciplinary Management of a Patient with Hepatocellular Carcinoma Affected with COVID 19". Acta Scientific Clinical Case Reports 3.1 (2022): 55-58.

Copyright

Copyright: © 2022 Soundappan Somasundaram., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.